Human papillomavirus (HPV)-induced oropharyngeal squamous cell carcinoma (OPSCC) remains increasing worldwide. We aimed to investigate if the HPV-prevalence of OPSCC in the Netherlands is rising as well, also in female patients. In addition, we evaluated the association between HPV-positive OPSCC and suspicious Pap results of the cervix in these female patients. Patients with OPSCC treated in the period 2000-2015 at the VU University Medical Center Amsterdam, were included (n 5 926). The presence of an oncogenic HPV infection was determined by p16-immunostaining, followed by a high-risk HPV general primer 51/61 DNA PCR on the p16-immunopositive cases. A review of pathology reports in all female patients (n 5 305) was undertaken to identify cytological signs of HPV-related (pre)cancer of the cervix. 
Introduction
Human papillomavirus (HPV) infection accounts for approximately 5.2% of the worldwide human cancer burden. 1, 2 The role of HPV in cervical oncogenesis has been established 40 years ago. Between 1974 and 1976, researchers postulated and analyzed a possible role of HPV in cervical cancer. [3] [4] [5] The first HPV types were isolated directly from cancer biopsies of the cervix; and HPV16 and HPV18 genomes were cloned in 1983 and 1984, respectively. 6, 7 Subsequent years of research have resulted in a better understanding of viral oncogene activities and in a more detailed knowledge of the natural history of HPV infection. It has become apparent that the role of HPV is more far-reaching than could be anticipated, with a strong link between HPV infection and the development of not only cervical but also vaginal, vulvar, penile, anal as well as head and neck cancers. 2, [8] [9] [10] [11] In head and neck cancer patients, infection with HPV is particularly related to those carcinomas that arise in the oropharyngeal region (OPSCC). Epidemiologic evidence has revealed a rapid increase in the attributable fraction of HPV-induced OPSCCs. In the Netherlands we noted an increase in HPVpositive OPSCC from 5% in 1990 till almost 30% in 2010. 12 Moreover, an increasing incidence of OPSCC in general was described in this period. [13] [14] [15] [16] [17] [18] [19] In the United States, HPV now causes the majority of OPSCC and the total number of the cases is expected to surpass the number of cervical cancers by the year 2020, assuming that the current trend of increasing incidence of oropharynx cancer continues. 2 In our study, we aimed to investigate whether the attributable fraction of HPV-positive OPSCC in the Netherlands remains rising and whether this differs for male and female patients. Previously, it was shown that patients with cervical cancer or precancerous lesions develop significantly more second primary cancers in the head and neck region compared to the general population. 2, [20] [21] [22] Chaturvedi et al., using data from 104,760 1-year survivors of cervical cancer calculated standardized incidence ratios (SIRs) for second primary cancers. In these women, the calculated SIR of developing second primary tumors in the head and neck was significant for the pharynx (2.28) and the mouth (1.98). 23 Balamurugan et al. also examined the incidence of second primary tumors in cervical cancer patients and observed a slightly elevated SIR (1.96) for oral cavity and pharyngeal cancer. 20 However, little is known about a history of cervical precancer or development of suspicious Pap results in female patients diagnosed with an HPV-positive OPSCC. The second aim of our study was therefore to evaluate if female patients with an HPV-positive OPSCC had a more frequent history of suspicious Pap results of the cervix compared to female patients with HPV-negative OPSCC.
Materials and Methods

Study design
Our study included all patients with OPSCC that were treated at VU University Medical Center (VUmc) in the period 2000-2015 (n 5 947). In total, 926 of 947 biopsies could be obtained from the pathology archives. Data from 2000 to 2006 were previously published, data from the years 2007 to 2015 have been added. 24 The patients were identified through the Netherlands Comprehensive Cancer Organisation. Patient characteristics, information on smoking behavior (one pack year 5 20 cigarettes a day during one year) and alcohol consumption (one unit year 5 one alcohol-containing drink a day during one year) as well as clinical outcome were obtained from the patient files.
The presence of HPV was detected using pre-treatment formalin-fixed, paraffin-embedded (FFPE) biopsies. Eligible samples included histopathologically confirmed invasive squamous cell carcinoma of the oropharynx (International classification of diseases for Oncology, [ICD-10] codes C019, C051, C052, C090-C099 and C100-C109).
Approval for this retrospective study was obtained from the Institutional Review Board and use of tissue specimen and patient data adheres to the guidelines for approved use of human tissue (www.federa.org.).
All female patients with OPSCC (n 5 308) were selected. The presence of (pre)cancerous cervical lesions, as defined by abnormal Pap smears, was determined by the pathologist (EB) through a search in the national pathology database (PALGA). Cervical lesions were divided into categories according to the Papanicolaou classification which is connected to the KOPAC-B encryption.
25,26
HPV testing
Paraffin sections were prepared according to the sandwich method: the first and last sections were stained by haematoxylin and eosin to check for tumor presence. Sections of 3 mm were made for p16-immunostaining. A total of four sections of 10 mm were used for DNA isolation and HPV DNA detection. Precautions taken to avoid cross-contamination, have been described before. USA) on a BONDmax (Leica, Amsterdam, the Netherlands) automated platform. As a negative control, a monoclonal mouse antibody against Rat oxytocin-related neurophysin was used. Two independent observers performed evaluation of the slides and consensus was achieved in all cases. Scoring of the slides was performed as described before.
12
The GP51/61-PCR with enzyme-immuno-assay (EIA) read-out was used for DNA detection of 14 high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, 66 and 68). 27 Subsequent genotyping of the virus was performed by bead-based array on the Luminex platform. 28 Sample quality after DNA extraction was controlled by b-globin PCR (amplicon size 100 bp). 29 All GP51/61 negative PCR results had to be positive for the b-globin PCR. Otherwise the sample was considered as non-diagnostic in the analysis, but this did not occur. When p16-immunostaining was positive, but GP 51/61 PCR was negative, type-specific PCR for HPV16 was performed in addition using primers in the E7 gene to exclude false-negative findings by viral integration.
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Statistical Methods
The 
Results
Patient characteristics and HPV-detection
All retrieved biopsies were scored for oncogenic HPV according to the validated test algorithm for HPV detection. 12 P16-IHC was scored positive in 315 of 926 samples (34.0%). The GP51/61 HPV DNA PCR with enzyme-immuno-assay read-out was used for detection of 14 high risk HPV types (i.e., HPV 16, 18, 31, 33, 35, 39, 45 , 51, 56, 58, 59, 66 and 68). Cases negative with the GP51/61 assay were also tested for HPV16 by E7 primers. In total, 272 of 315 (86%) p16-positive cases were HPV DNA-positive and considered true HPV-positive.
The association of patient variables and tumor characteristics was analyzed in relation to tumor HPV status (Table 1) . Patients with HPV-positive OPSCC were less likely to have a history of heavy smoking (>24 pack years) and excessive alcohol consumption (>149 unit years) as compared to patients with HPV-negative OPSCC (p < 0.001). Patients with HPV-positive tumors had a more advanced nodal stage, but less advanced primary tumor stage (T-stage). There were no significant differences in patient characteristics in the patient group of which the tumor biopsies could not be retrieved (p > 0.05).
Time trend analysis
In Figure 1 , the proportion of patients with an HPV-positive OPSCC, stratified per year is depicted. A highly significant increase in the HPV-attributable fraction of OPSCC was observed in the period 2000-2015 by the Cochran-Armitage test for trend (p < 0.001).
An increasing trend in HPV prevalence was also noted with regard to the female patients. Due to the relatively small number of female patients, we had to stratify the patients per 5-year interval; again we observed a significant increase 31 This is in line with the increase in European Age-Standardized Rates (ESR)-standardized incidence of OPSCC in both males and females during the last decades. 13 Hence, these denominator data show that the increase in HPV-attributable fraction of OPSCC at the VU University Medical Center reflects the general increase in incidence of OPSCC in the Netherlands, and might form the likely cause thereof.
Suspicious Pap cytology results in female OPSCC patients
Among the female patients with an HPV-positive OPSSC (n 5 70), the result of one or more cervical Papanicolaou 
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(Pap)-test could be identified in the medical history of 56 of 70 patients (80.0%). In 47 of those 56 patients (83.9%) a Pap smear 3a was diagnosed, while in 9 of 56 patients (16.1%) a Pap-test 3b was recorded.
A cervical Pap-test result was identified in 168 of 238 (70.6%) female patients with an HPV-negative OPSSC. In 161 of those 168 patients (95.8%) a Pap-test 3a was recorded and only 7 of 168 patients (4.2%) had a Pap-test 3b in their medical history.
As depicted in Table 2 , in the HPV-positive OPSCC group, significantly more patients had a recorded Pap-test 3b in the medical history (v 2 test p 5 0.003, Fisher's exact test p 5 0.006). In Table 3 , the development of the suspicious Pap results of the 9 HPV-positive OPSCC patients is further specified. Noteworthy is that 8 of 9 patients developed first the cervical cytological abnormalities, before developing the HPV-positive OPSCC (Table 3) .
Discussion
In this retrospective study, we demonstrated an overall increase in the proportion of HPV-positive OPSCC at the VU University Medical Center Amsterdam, from14.0% in 2000 to 48.1% in 2015. Moreover, the total number of OPSCCs patients also increased from 2000 to 2015. Although absolute numbers may be flawed by population characteristics, also the incidence of OPSCC, expressed as ESR rates, continues to increase already for decades in both males and females. 13 The increase in HPV-positive OPSCC as well as the general increase in OPSCC corresponds with published data in the United States and other European countries. [14] [15] [16] [17] [18] [19] However, in a recent report from the United Kingdom, the proportion of HPV-positive OPSCCs remained static at approximately 50% in 2011. 32 As the number of female OPSCC patients per year was limited, we had to stratify the patients in 5-year intervals; but a significant increase in HPV-attributable OPSCC in female patients could be observed from 2000 till 2015.
Female patients with an HPV-positive OPSCC had a history of significantly more suspicious Pap results (i.e., Pap smear 3b) compared to the HPV-negative Group (16.1% vs. 4.2%). Of note, the frequency of suspicious Pap results in the HPVnegative OPSCC group was still higher compared to the general Dutch population. In the Dutch cervical cancer screening program, this result (pap 3b-5) is normally obtained in 0.8% of cases. 33 An explanation could be that patients who develop an HPV-driven OPSCC, are more susceptible to other HPV-driven malignancies and/or are at increased risk by life style factors.
The relation between HPV-induced cervical cancer and OPSCC may have several explanations. First of all, it is assumed that this epidemiologic association reflects coinfection of HPV between cervix and oropharynx through sexual behavior. 34 Other possibilities include a susceptibility to the oncogenic effects of HPV or exposure to other common risk factors such as smoking. 17, 35 HPV-positive OPSCC and cervical cancer show similarities in terms of pathogenesis Findings from other studies suggest similar molecular routes in the pathogenesis of HPV-positive OPSCC and cervical cancer. HPV-mediated carcinogenesis likely acts through a common mode of cellular transformation, such as p53 and pRb tumor suppressor pathway inactivation by the viral oncoproteins. 7, 36 A recent study by Mirabello et al. revealed a high inter-individual variability in HPV16 genomes. In addition, within-lineage variation occurs in specific regions of the viral genome. These genome variants might impact HPV carcinogenicity. Future research will reveal whether HPV transmission, clearance and persistence in the upper-aerodigestive tract might relate to these sequence variants. 37 As mentioned before, an association between women with suspicious Pap results and the subsequent development of OPSCC has been described before. 2, 20, 21 This might have implications for the development of prevention and early detection strategies for HPV-positive OPSCC in these cervical (pre)cancer patients. Vice versa, Biron et al. showed that women presenting with OPSCC as the primary tumor, have also a significantly increased risk of developing HPV-related genital cancers. Their results showed a significantly increased overall incidence (at least 25 times larger) of cervical cancer in women with OPSCC in comparison to the control population. 38 Interestingly, our study shows that most patients developed a suspicious Pap result >10 years before developing an HPVpositive OPSCC. We identified only one patient who developed the suspicious Pap result after being treated for the HPVpositive OPSCC. However, we discovered that this patient did not adhere to the screening program for cervical cancer before diagnosis of her OPSCC, and might have had a concomitant cervical lesion at the time of or years before OPSCC diagnosis.
We were not able to test for HPV on the Pap-specimen, as these had been obtained in a population-based screening program and were discarded. However, a comprehensive study on the global burden of HPV-associated cancers attributes HPV infection to 100% of all cervical cancers. 39 In the current screening program in the Netherlands (since 2016), all patients are being tested for HPV, so these data will become available. In a future study, it would be interesting to analyze whether the cervical and oropharyngeal lesions are caused by the same HPV type and sequence variants. Using this information, we would acquire more knowledge about eventual (co)infection of the cervix and oropharynx, and the potential role of the sequence variants.
In conclusion, a continuous increase in the proportion of HPV-positive OPSCC was demonstrated in the period 2000-2015, for both male as well as female patients. In the female patients with HPV-positive OPSCC an association was found with presence of suspicious Pap results in the medical history, in general before the oropharyngeal tumor developed. 
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